161 related articles for article (PubMed ID: 8375428)
1. Neuroprotection by anti-oxidant strategies in Parkinson's disease.
LeWitt PA
Eur Neurol; 1993; 33 Suppl 1():24-30. PubMed ID: 8375428
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
3. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
Youdim MB; Riederer P
Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and animal studies of Parkinson's disease.
Oertel WH; Kupsch A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
[TBL] [Abstract][Full Text] [Related]
7. Free radicals and their scavengers in Parkinson's disease.
Yoshikawa T
Eur Neurol; 1993; 33 Suppl 1():60-8. PubMed ID: 8375435
[TBL] [Abstract][Full Text] [Related]
8. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
Knoll J
J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
[TBL] [Abstract][Full Text] [Related]
9. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
10. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
Mercuri NB; Calabresi P; Bernardi G
Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
[No Abstract] [Full Text] [Related]
11. Deprenyl and the issue of neuroprotection.
Vingerhoets FJ; Uitti RJ; Calne DB
Eur Neurol; 1994; 34(1):1-3. PubMed ID: 8137832
[No Abstract] [Full Text] [Related]
12. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
13. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
Olanow CW
Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
[TBL] [Abstract][Full Text] [Related]
14. [Medicamentous strategy for improving the quality of life in the senescence].
Knoll J
Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
[TBL] [Abstract][Full Text] [Related]
15. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
16. Type B monoamine oxidase and neurotoxins.
Naoi M; Maruyama W
Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective strategies in Parkinson's disease : an update on progress.
Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
[TBL] [Abstract][Full Text] [Related]
18. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
19. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
20. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
